Teva Specialty & Biosimilar Product Pipeline
by development stage - July 2021
Teva’s Global R&D organization helps propel the company’s mission to be a global leader in generics and biopharmaceuticals. From early development to commercial launch of small molecules, novel biologics and biosimilars, our uniquely integrated “One Teva” drug development model combines our strength in generics with our knowledge of innovative drug development. We understand the many ways that health impacts people’s lives, and will continue to invest in new breakthrough treatments, offer innovative solutions, and find new ways to extend and expand patient care beyond medicine.
Technology Platforms:
Under Regulatory Review
Pre Submission
Phase 3
Phase 2
Phase 1
Pre-clinical
Download a PDF version of Teva Specialty and Biosimilar Product Pipeline
Download PDFTeva specialty pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.
*Visit https://www.tevausa.com/our-products/article-pages/Specialty-Medicines-List/ for full prescribing information for these products in the US.
Pipeline is current as of July 2021
-
Back to contents.
In partnership with Alvotech in US.
-
Back to contents.
These uses are investigational. Fremanezumab is approved in the United States for another indication as AJOVY® (fremanezumab-vfrm) injection*.
-
Back to contents.
In partnership with Regeneron.
-
Back to contents.
These uses are investigational. Deutetrabenazine is approved in the United States for other indications as AUSTEDO® (deutetrabenazine) tablets*.
-
Back to contents.
In partnership with BioEq in Europe, Canada, Israel and global markets
